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Abstract
Background: Previous studies examining the use of direct oral anticoagulants
(DOACs) in atrial fibrillation (AF) have largely focused on patients newly initiating
therapy. Little is known about the prevalence/patterns of switching to DOACs among
AF patients initially treated with warfarin.
Hypothesis: To examine patterns of anticoagulation among patients chronically man-
aged with warfarin upon the availability of DOACs and identify patient/practice-level
factors associated with switching from chronic warfarin therapy to a DOAC.
Methods: Prospective cohort study of AF patients in the NCDR PINNACLE registry
prescribed warfarin between May 1, 2008 and May 1, 2015. Patients were followed
at least 1 year (median length of follow-up 375 days, IQR 154-375) through May
1, 2016 and stratified as follows: continued warfarin, switched to DOAC, or
Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; NCDR, National
Cardiovascular Disease RegistryPINNACLEPractice Innovation and Clinical Excellence; CKD, chronic kidney disease; GFR, glomerular filtration rate.
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discontinued anticoagulation. To identify significant predictors of switching, a three-
level multivariable hierarchical regression was developed.
Results: Among 383 008 AF patients initially prescribed warfarin, 16.3% (n = 62 620)
switched to DOACs, 68.8% (n = 263 609) continued warfarin, and 14.8%
(n = 56 779) discontinued anticoagulation. Among those switched, 37.6% received
dabigatran, 37.0% rivaroxaban, 24.4% apixaban, and 1.0% edoxaban. Switched
patients were more likely to be younger, women, white, and have private insurance
(all P < .001). Switching was less likely with increased stroke risk (OR, 0.92; 95%CI,
0.91-0.93 per 1-point increase CHA2DS2-VASc), but more likely with increased
bleeding risk (OR, 1.12; 95%CI, 1.10-1.13 per 1-point increase HAS-BLED). There
was substantial variation at the practice-level (MOR, 2.33; 95%CI, 2.12-2.58) and
among providers within the same practice (MOR, 1.46; 95%CI, 1.43-1.49).
Conclusions: Among AF patients treated with warfarin between October 1, 2010
and May 1, 2016, one in six were switched to DOACs, with differences across
sociodemographic/clinical characteristics and substantial practice-level variation. In
the context of current guidelines which favor DOACs over warfarin, these findings
help benchmark performance and identify areas of improvement.
K E YWORD S
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1 | INTRODUCTION
Anticoagulation significantly decreases stroke risk in atrial fibrillation
(AF).1 Although warfarin was previously the standard treatment for
stroke prevention in AF, direct oral anticoagulant (DOAC) medications
have been approved for nonvalvular AF since 2010. Compared to
warfarin, these medications have been shown to provide more consis-
tent anticoagulant effect, substantially reduce the risk of intracranial
hemorrhage, have fewer interactions with other drugs/food, and do
not require international normalized ratio (INR) monitoring.2,3 As a
result, the 2019 update to the American College of Cardiology (ACC)/
American Heart Association (AHA)/Heart Rhythm Society (HRS) AF
guidelines favor the use of DOACs over warfarin for stroke preven-
tion in nonvalvular AF with a class 1A recommendation.4
Previous studies from the National Cardiovascular Disease
Registry's (NCDR) Practice Innovation and Clinical Excellence
(PINNACLE) registry have examined patterns of DOAC use in AF, and
have noted disparities in DOAC use based on sex, race, and insurance
status.5-9 However, these analyses have focused exclusively on
patients newly initiating anticoagulation for AF. There is limited data
evaluating how commonly patients on warfarin are switched to
DOACs and why they are switched.7 The NCDR PINNACLE registry
longitudinally follows patients with AF, providing insight into patterns
of switching oral anticoagulant therapy and identifying patient and
practice-level factors associated with switching.10
Accordingly, we sought to examine patterns of anticoagulation
among patients with AF treated with warfarin, determine predictors
of switching from warfarin to DOACs, and identify potential
disparities in care based on sociodemographic and clinical factors. We
hypothesized that there would be significant disparities in switching
patterns and substantial patient/practice-level variations.
2 | METHODS
2.1 | Data source
The NCDR PINNACLE registry is a prospective outpatient quality
improvement registry that was created by the ACC in 2008.10 In this
registry, both academic and private practices collect longitudinal data
pertaining to the care of patients with AF, coronary artery disease,
hypertension, and heart failure. This includes demographics, medical
comorbidities, medications, and practice/provider data. These data
are collected from the patients' charts using a standardized collection
tool to obtain and transmit data. De-identified data was extracted
from an electronic medical record under a quality improvement model,
with approval from an institutional review board and informed con-
sent waived. Rigorous data definitions and periodic data quality audits
are conducted to maintain NCDR data quality assurance.11 Analysis of
the data was performed at the Baim Institute for Clinical Research.
2.2 | Study population
The study cohort included all patients with nonvalvular AF, in the PIN-
NACLE dataset with at least one warfarin prescription between
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January 1, 2008 and May 1, 2015. Patients were followed longitudi-
nally in PINNACLE and stratified based upon their anticoagulation
between October 1, 2010 and May 1, 2016 as follows: (a) continued
warfarin, (b) switched to a DOAC, and (c) discontinued anti-
coagulation. Patients were substratified by the date of index visit
(2010-2011, 2012-2013, and 2014-2016) and time after index visit
(30 days, 90 days, 180 days, 365 days, and more than 365 days).
Patients were considered to have switched if they had a DOAC
recorded on two consecutive visits in the registry. Patients were
excluded if they were younger than 18 years of age, or did not have a
second encounter after the initiation of warfarin. Additionally,
patients were excluded if they had a history of cardiac valve surgery
(valve replacement/valvular AF) or systemic embolism recorded in the
registry, in order to analyze patients who were potentially eligible to
switch.
2.3 | Statistical methods
The primary outcome of this study was the proportion of patients
with AF treated with warfarin that were switched to a DOAC and the
proportion switched to each specific agent. We calculated the propor-
tion of patients with AF treated with warfarin that were switched to a
DOAC, and then calculated the proportion switched to each specific
agent (dabigatran, rivaroxaban, apixaban, and edoxaban). Among the
patients who were switched, we calculated the proportion who were
subsequently switched back to warfarin, to a different DOAC, or had
all anticoagulation discontinued. The mean/median number of visits in
the PINNACLE dataset and the mean/median time of follow-up were
also obtained. Additionally, patterns were determined after stratifying
patients based on CHA2DS2-VASc score (groups: score 0-1, score 2-3,
and score 4 or more). For the population of patients who were
switched, demographic, clinical, laboratory, and medication informa-
tion was compared across groups.
Categorical variables are reported as numbers (percentages) and
continuous variables are reported as medians (25th and 75th percen-
tiles) or means (SD). The significance of observed differences was
tested using a Wilcoxon rank sum test or t-test for continuous vari-
ables and chi-square test for categorical variables. To identify signifi-
cant predictors of switching, a multivariate model was created,
including all variables with P < .1 in bivariate testing.
The multivariate analyses of clinical variables were modeled in dif-
ferent ways: (a) each component of the CHA2DS2-VASc individually,
(b) CH2ADS2-VASc modeled per 1-point increase along with nonco-
mponent of the CHA2DS2-VASc covariates, (c) CHA2DS2-VASc
modeled as 2-6 vs 0 or 1 without HAS-BLED score, and (d) including
both CHA2DS2-VASc scores and HAS-BLED scores modeled per
1-point increase. Since there are co-linear variables in the risk scores,
the CHA2DS2-VASc score was modeled both with and without the
HAS-BLED score. Practice-level analyses were conducted by aggre-
gating patients initially managed with warfarin at the practice-level.
The distribution of the proportion of patients receiving warfarin who
were switched to a DOAC was determined across practices. After the
distribution was examined, additional practice-level analyses were
conducted by stratifying practices into tertiles based on the propor-
tion of patients who were switched to a DOAC (tertiles were arranged
from lowest switching rates to highest).
To measure practice variation, the median odds ratio (MOR)
was used. The MOR is able to provide cluster-level variance when a
multilevel regression analysis is performed and can assess variation
in a mixed effects model. An MOR >1.2 suggests clinically signifi-
cant variation in the outcome among a unit after adjustment for
fixed effects. In this analysis, an MOR >1.2 suggests clinically signifi-
cant variation among practices in switching from warfarin to a
DOAC.12
3 | RESULTS
3.1 | Study cohort
There were 485 986 patients in the PINNACLE registry with AF on
warfarin between May 1, 2008 and May 1, 2015. Of these patients,
102 978 were excluded from the analysis due to cardiac valve sur-
gery, systemic embolism, age less than 18, missing sex, or missing fol-
low up encounters (Figure 1). This resulted in 383 008 patients
included in the analysis with at least one prescription for warfarin for
AF between May 1, 2008 and May 1, 2015, who were eligible to be
switched to a DOAC. Overall demographic, clinical, and practice-level
characteristics of the study population from the PINNACLE registry
are shown in Table S1. The mean age of the population was 73.6
(SD 10.7) years, 57.5% were male (n = 220 097), 69.0% were white
(n = 264 088), and 3.2% (n = 12 283) were black or African American.
Chronic kidney disease (CKD) was seen in 2.2% (n = 8467). Among
patients in this analysis, 0.8% (n = 2136) had a glomerular filtration
rate (GFR) 12-29 mL/min and 0.1% (n = 548) a GFR < 15 mL/min. The
median CHA2DS2-VASc score was 4.0 (IQR 3.0-5.0) and HAS-BLED
score was 2.0 (IQR 2.0-3.0). Practices were geographically distributed
across the country, with 52.1% in the Southern region and 38.1% in
urban locations.
3.2 | Switching from warfarin to DOAC
Of the 383 008 patients with AF on warfarin, 16.3% (n = 62 620)
were switched to a DOAC, while 68.8% (n = 263 609) were contin-
ued on warfarin and 14.8% (n = 56 779) had anticoagulation discon-
tinued (Figure 1). Among those who were switched to DOACs,
37.6% (n = 23 518) were switched to dabigatran, 37.0%
(n = 23 195) to rivaroxaban, 24.4% (n = 15 295) to apixaban, and
1.0% (n = 612) to edoxaban. The median (25th and 75th percentiles)
number of visits from the baseline visit to switching to DOAC was
3.0 (2–5) with mean value of 4.2 (SD 3.6) visits. The median (25th
and 75th percentile) duration from the baseline visit to switching to
DOAC was 336.0 (118-767) days with mean duration of 517.0
(SD 530.2) days.
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Patterns of switching stratified by CHA2DS2-VASc score tertiles are
shown in Figure S1. Among patients with a CHA2DS2-VASc score of 0-1
(n = 34 163), 20.7% (n = 7083) were switched to DOAC, 58.8%
(n = 20 077) were continued on warfarin, and 20.5% (n = 7003) had anti-
coagulation discontinued. For patients with a CHA2DS2-VASc score of
2-3 (n = 144 761), 17.1% (n = 24 769) were switched to DOAC, 68.4%
(n = 99 064) were continued on warfarin, and 14.5% (n = 20 928) had
anticoagulation discontinued. Among patients with a CHA2DS2-VASc
score of 4 or more (n = 204 084), 15.1% (n = 30 768) were switched to
DOAC, 70.8% (n = 144 468) were continued on warfarin, and 14.1%
(n = 28 848) had anticoagulation discontinued. Switching among
patients with a GFR 15-29 mL/min was 12.3% (n = 262) and among
patients with a GFR < 15 mL/min was 6.4% (n = 35).
3.3 | Predictors of switching
Baseline demographic, clinical, and practice characteristics of the
overall population with AF treated with warfarin (Table S1), patients
who were and were not switched (Table S2), and within specific medi-
cation groups (Table S3) are shown. Patients switched from warfarin
to DOACs tended to be younger, diabetic, have private insurance, and
a history of prior stroke; while those who were not switched tended
to have coronary artery disease and heart failure (all P < .001). The
mean CHA2DS2-VASc score for those switched was 3.5 (SD 1.7) and
for those not switched 3.7 (SD 1.6); the mean HAS-BLED score for
those switched was 2.2 (SD 1.0) and for those not switched was 2.2
(SD 0.9, all P ≤ .005).
F IGURE 1 Study population
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3.4 | Multivariate models for predictors of
switching to a DOAC
A multivariate hierarchal regression model with the CHA2DS2-VASc
score and noncomponent covariates (Figure 2a) showed that
switching to DOACs was significantly more likely among patients of
white race (OR, 1.22; 95%CI, 1.14-1.30), with private insurance (OR,
1.10; 95%CI, 1.06-1.14), and those cared for by an electrophysiologist
(OR, 1.18; 95%CI, 1.10-1.27). Switching was significantly less likely
per 1-point increase in CHA2DS2-VASc (OR, 0.92; 95%CI, 0.91, 0.93)
and at practices in the Midwest as compared with the Northeast
region (OR, 0.47; 95%CI, 0.32-0.69). A multivariate hierarchical
regression model comparing CHA2DS2-VASc scores to scores of 0-1
showed that the odds of switching decreased as the CHA2DS2-VASc
score increased when modeled both with and without the HAS-BLED
score (Figures 2b and S2). Patients with higher HAS-BLED scores, per
1-point increase, showed more propensity to switch (OR, 1.12; 95%CI
1.10-1.13).
The findings were similar when the multivariate hierarchal
regression model included clinical covariates of the CHA2DS2-VASc
score (Figure S3). Specifically, switching to DOACs was more likely
with white race vs non-white (OR, 1.38; 95%CI, 1.29-1.47), private
insurance vs other (OR, 1.08; 95%CI, 1.04-1.12), prior stroke/tran-
sient ischemic attack (TIA) (OR, 1.05; 95%CI, 1.01-1.10), and
(A)
(B)
F IGURE 2 Multivariate hierarchical
regression model with, A, CHA2DS2-
VASc and noncomponent covariates; B,
CHA2DS2-VASc and HAS-BLED scores
(CHA2DS2-VASc scores are compared to
reference score of 0 or 1). Variables with
nonsignificant associations included
History of Stable Angina (OR 1.05, 95%
CI 0.99-1.11), Ethnicity: Hispanic or
Latino (vs Not) (OR 1.03 95%CI
0.89-1.19), Current or Former Smoker
(vs Never Smoker) (OR 1.01 95%CI
0.98-1.04), Other (vs Nurse Practitioner)
(OR 1.00 95%CI 0.84-1.19), Physician
Provider (vs Nurse Practitioner)
(OR 1.00 95%CI 0.91-1.10), South
Region (vs Northeast) (OR 0.72 95%CI
0.48-1.10), and West Region
(vs Northeast) (OR 0.91 95%CI
0.65-1.28)
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electrophysiologists vs nonelectrophysiologist cardiologist (OR,
1.16; 95%CI, 1.08-1.24). Switching was less likely with age per
10-year increase (OR, 0.82; 95%CI, 0.81-0.83), sex: male vs female
(OR, 0.92; 95% CI, 0.90-0.95), history of heart failure (OR, 0.85;
95%CI, 0.82-0.88), history of diabetes (OR, 0.97; 95%CI,
0.94-1.00), and Midwest vs Northeast Region (OR, 0.47; 95%CI,
0.32-0.68).
3.5 | Multiple switching
Among the 62 620 patients switched to a DOAC, 4.7% (n = 2960)
were switched back to warfarin, 7.5% (n = 4692) were switched to
another type of DOAC, and 4.6% (n = 2880) eventually discontinued
all forms of anticoagulation (Figure S4). A visual representation of
multiple changes in anticoagulation is shown in a flow cart with the
width of each connection proportional to the number of patients
switched (ie, a Sankey diagram; Figure 3).
3.6 | Practice variation in switching
There was substantial variation in switching patterns at the practice-
level (MOR, 2.31; 95%CI, 2.11-2.56) and for providers within the
same practice (MOR, 1.46; 95%CI, 1.43-1.49). A graphical representa-
tion of practice variation in switching to DOACs among 355 practices
(each practice is represented by a number on the x-axis, arranged with
increasing numbers representing a larger proportion of patients
switched in that practice) is shown in Figure 4.
The 355 practices were divided into tertiles (arranged from low-
est switching rates to highest) based on the proportion of individuals
switched from warfarin to DOACs (Table S4), with tertile 1 comprised
practices with the lowest switching rates. Practices with higher
switching rates tended to have higher clinical volume, more electro-
physiologists, and were more likely to be located in the West region.
Tertile 1 was comprised of 36.8% urban locations with mean
(SD) visits per year of 11 562 (SD 18 619), 84.9% physician providers,
and 5.9% electrophysiologists. Tertile 2 was comprised 45.0% urban
F IGURE 3 Sankey diagram of multiple anticoagulant switching
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locations, mean (SD) visits per year of 18 259 (SD 17 351), 83.2%
physician providers, and 8.2% electrophysiologists. Tertile 3 was com-
prised 33.9% urban locations, mean (SD) visits per year 22 253
(SD 27 024), 84.5% physician providers, and 9.6%
electrophysiologists.
3.7 | Timing of switching
As time progressed, the proportion of individuals switched from war-
farin to DOACs increased (Table S5). Among patients switched, 13.8%
(n = 8639) were switched from May 2010 to December 2011, 34.2%
(n = 62 620) from January 2012 to December 2013, and 52.0%
(n = 32 566) from January 2014 to April 2016. Choice of agent varied,
with the majority of patients who were switched early receiving
dabigatran, but rivaroxaban and apixaban became the predominant
agents for later time periods in the analysis. The majority of switches
occurred more than 1 year after the index visit (Table S6), with 47.2%
(n = 29 560) >365 days after the first visit.
4 | DISCUSSION
This analysis from a large, national outpatient registry demonstrates
that approximately 1 in 6 AF patients treated with warfarin, who were
eligible to be switched to a DOAC, were switched between October
1, 2010 and May 1, 2016. There were significant differences in
switching based on clinical/sociodemographic factors, and substantial
variation in care patterns across practices. This relatively low rate of
switching represents an important target for improvement as DOACs
have been established as first line therapy for most patients with non-
valvular AF.4
The updated ACC/AHA/HRS guidelines recommend DOAC ther-
apy over warfarin given data demonstrating comparable efficacy with
less bleeding. A meta-analysis of randomized controlled trials demon-
strated that DOACs provide significant reduction in stroke, intracra-
nial hemorrhage, and mortality with similar major bleeding compared
to warfarin.13 Against this backdrop, previous analyses from the PIN-
NACLE registry have shown higher rates of DOAC initiation in AF
than the switching we observed, with approximately 60% of individ-
uals newly initiated on anticoagulation receiving a DOAC.5-9
Potential explanations for the relatively low rate of switching
include therapeutic inertia, where providers may not choose to make
a change to anticoagulation therapy if a patient has been stable on
warfarin without adverse events. Additionally, when DOACs were
new, some providers may have waited for accumulating evidence of
safety and benefit prior to changing therapy. This may explain why
more switching occurred later in the study. Providers may have also
chosen to not switch patients they believed had adequate Time in
Therapeutic Range (TTR) on warfarin. European guidelines suggest
that providers can consider continuing warfarin if patients are able to
maintain a TTR on warfarin ≥70% of the time.14,15 However, studies
suggest that less than 50% of patients on warfarin are able to main-
tain a TTR ≥70% at 6 months and a smaller proportion of these
patients are able to maintain a TTR ≥70% at 12 months.16 Finally, cost
is a significant barrier to DOAC use for many patients in the United
States, but is less of an issue in Europe where there is widespread pre-
scription drug coverage. This is further emphasized by a study from a
Danish cohort that showed significantly higher rates of switching than
we observed in our analysis.17
Broadly speaking, the substantial practice level variation suggests
that there are multiple mechanisms underlying these findings. Both at
the practice level and among providers within the same practice, there
was substantial variation in switching patterns, emphasizing a lack of a
F IGURE 4 Practice variation for
patients switched to DOAC. *Proportion
of patients switched at each of the
355 participating centers
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unified approach to switching patients from warfarin to DOACs.
With some practices switching approximately 65% of patients, while
others did not switch any, this highlights the need for additional
performance improvement efforts to better align care with practice
guidelines.
Another key finding from our analysis is that switching was less
prevalent among patients with increasing age, non-white race, those
without private insurance, and men. There have been numerous dis-
parities in many aspects of AF management, including initiation of
DOACs and ablation.5-9 Although predictors of switching have not
been extensively examined in the literature, disparities in DOAC initia-
tion have been observed based on age, race, insurance status, geo-
graphic region, female sex, lower household income, higher stroke
risk, and higher bleeding risk.18-19 In a Danish study that specifically
focused on switching from warfarin to DOACs, it was similarly
observed that younger age, female sex, history of stroke, and history
of bleeding were predictors of switching.17 Our analysis adds to this
literature and further heightens the need for quality improvement
efforts to address and close these disparities.
It is also notable that switching was more prevalent with
increased bleeding risk (based on HAS-BLED scores) but less preva-
lent with increased stroke risk (based on CHA2DS2-VASc scores). We
know from other studies that bleeding avoidance is an important
driver of decision-making20 and represents an important assessment
and reassessment of anticoagulation choices. Providers may have
been cautious to switch patients at higher risk of stroke because war-
farin was the established agent and because of the inertia to change
in the absence of a specific clinical issue. Conversely, the ability to
lower bleeding risk with a specific therapeutic intervention may repre-
sent a key element in decision-making. The higher likelihood of
switching per 1-point increase in HAS-BLED may be related to the
lower bleeding risk of DOAC therapy compared to warfarin.21-23
The lower likelihood of switching among individuals per 1-point
increase in the CHA2DS2-VASc score differs from previous registry
data on DOAC initiation. Numerous studies have shown that DOAC
initiation was less likely with both increasing stroke and bleeding
risk.6,7,14 This was believed to be related to the lack of commercially
available bleeding reversal agents and commonalities among compo-
nents of the CHA2DS2-VASc and HAS-BLED scores, meaning a higher
stroke risk correlates with a higher bleeding risk. Although reversal
agents for DOACs are now available, these were not in wide use dur-
ing the majority of our analysis. As DOAC reversal agents become
more widely available, providers may be more likely to switch patients
in the future.
Another significant predictor of switching was treatment by an
electrophysiologist. This observation may reflect either lack of com-
fort with these newer agents or decreased awareness of potential
benefits among nonsubspecialty practitioners. As a result, referrals to
electrophysiologists would impact which patients would be switched.
Lower rates of referrals to specialists have been reported in patients
post-MI among different racial and lower socioeconomic groups,24
and if such disparities are also present among patients with AF, this
would in turn affect switching to DOACs.
The relatively low rate of switching and the potential differences
observed in the PINNACLE registry may serve as an important perfor-
mance improvement target for treatment of patients with
AF. Switching patients from warfarin to DOACs is especially impor-
tant given the 2019 update to the ACC/AHA/HRS AF guidelines,
which favor DOACs over warfarin for stroke prevention with a class
1A recommendation.4 Increased cost and other barriers to switching
must be addressed, including patient perspectives and preferences.
The large degree of practice variation seen in this study highlights the
lack of a standardized approach for switching patients.
4.1 | Limitations
There were a few important limitations of this analysis. First, since the
PINNACLE registry contains data abstracted from practices participat-
ing in a quality improvement registry, it is possible that the data may
not be representative of other practices in the United States. This pro-
gram provides additional support to facilitate guideline recommended
treatments that may not be available in most practices. Information
such as accessibility to INR testing (ie, patients living far away from
testing centers), household income, and drug benefit plans would be
helpful to better define the role of cost in limiting switching. Addition-
ally, as with any clinical management decision, there are often relevant
factors that fall outside of information that can be collected in a regis-
try, such as patient preference and unmeasured practice variation.
Other factors such as nonadherence, or TTR with warfarin may have
affected anticoagulation patterns and switching to DOACs, but were
not collected in the PINNACLE registry. Another limitation is the rela-
tively sparse data on renal function available for our analysis. Renal
dysfunction is an important consideration in choosing anticoagulation
for AF patients and previously was a limitation for DOAC use,
although current guidelines now suggest it is reasonable to ant-
icoagulate these patients with apixaban.4 With a relatively low pro-
portion of patients with CKD, we were not able to systematically
examine the association of renal function on switching.
5 | CONCLUSIONS
In a contemporary cohort of patients with AF treated with warfarin,
switching from warfarin to DOACs was relatively uncommon.
Switching was less likely with rising stroke risk, but more likely with
higher bleeding risk. Additionally, there was significant practice varia-
tion in switching. In the context of the 2019 update to the ACC/AHA/
HRS guidelines, which favor DOACs over warfarin, these findings may
help benchmark performance and identify areas of improvement.
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